Editor’s note: A recording of the webinar presentation is included below.
While immunotherapies get most of the headlines, targeted cancer treatments have revolutionized oncology in recent years, changing the lives of some patients by homing in on genetically defined tumors.
Damian Garde, STAT’s national biotech reporter, takes a look at some of the most important targeted therapies recently approved and examines the pipeline of medicines yet to come. That means looking at the underlying science, the clinical data, and the often surprising costs associated with these drugs.
About the Author Reprints
